| Structural highlights
4l9h is a 1 chain structure with sequence from Human. Full crystallographic information is available from OCA. For a guided tour on the structure components use FirstGlance.
| | NonStd Res: | |
| Related: | 4l9c |
| Gene: | FBX7, FBXO7, HUMAN FBXO7 (HUMAN) |
| Resources: | FirstGlance, OCA, RCSB, PDBsum |
Disease
[FBX7_HUMAN] Parkinsonian-pyramidal syndrome. The disease is caused by mutations affecting the gene represented in this entry.
Function
[FBX7_HUMAN] Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Recognizes BIRC2 and DLGAP5.[1] [2]
Publication Abstract from PubMed
The FP (Fbxo7/PI31) domains found in the F-box protein Fbxo7 and the proteasome inhibitor PI31 mediate the homodimerization and heterodimerization of Fbxo7 and PI31. Fbxo7 is the substrate-recognition subunit of the SCF(Fbxo7) (Skp1-Cul1-F-box protein) E3 ubiquitin ligase that catalyzes the ubiquitination of hepatoma up-regulated protein (HURP) and inhibitor of apoptosis protein (IAP). Fbxo7 also interacts with proteins that are not substrates of the ubiquitin proteasome system, such as Cdk6 and PI31. Here, the crystal structure of the Fbxo7 FP domain is reported at 2.0 A resolution. The Fbxo7 FP domain adopts an alpha/beta-fold similar to that of the PI31 FP domain. However, an alpha-helix and three beta-strands in the Fbxo7 FP domain are longer than their counterparts in the PI31 FP domain. The differences in these secondary-structural elements are spatially clustered to define a more structured and extended C-terminal end of the Fbxo7 FP domain. The two FP domains also differ substantially in the length and conformation of the longest connecting loop. More importantly, structural differences between the two FP domains lead to drastically different modes of inter-domain protein-protein interaction. The inter-domain interface of the Fbxo7 FP domain is defined by the alpha-helical surface in one protomer and the beta-sheet surface in the other protomer, whereas for the PI31 domain it is defined by either the alpha-helical surfaces or the beta-sheet surfaces in both protomers. The inter-domain interaction of the Fbxo7 FP domain is much more extensive, featuring a larger contact surface area, better shape complementarity and more hydrophobic and hydrogen-bonding interactions. The Fbxo7 FP domain also has the potential to bind two protein partners simultaneously using the alpha-helical and beta-sheet surfaces. The results of this structural study provide critical insights into how Fbxo7 may dimerize (or multimerize) and interact with other regulatory proteins via the FP domain.
Structure of the FP domain of Fbxo7 reveals a novel mode of protein-protein interaction.,Shang J, Wang G, Yang Y, Huang X, Du Z Acta Crystallogr D Biol Crystallogr. 2014 Jan;70(Pt 1):155-64. doi:, 10.1107/S1399004713025820. Epub 2013 Dec 31. PMID:24419388[3]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
References
- ↑ Hsu JM, Lee YC, Yu CT, Huang CY. Fbx7 functions in the SCF complex regulating Cdk1-cyclin B-phosphorylated hepatoma up-regulated protein (HURP) proteolysis by a proline-rich region. J Biol Chem. 2004 Jul 30;279(31):32592-602. Epub 2004 May 15. PMID:15145941 doi:http://dx.doi.org/10.1074/jbc.M404950200
- ↑ Chang YF, Cheng CM, Chang LK, Jong YJ, Yuo CY. The F-box protein Fbxo7 interacts with human inhibitor of apoptosis protein cIAP1 and promotes cIAP1 ubiquitination. Biochem Biophys Res Commun. 2006 Apr 21;342(4):1022-6. Epub 2006 Feb 21. PMID:16510124 doi:http://dx.doi.org/10.1016/j.bbrc.2006.02.061
- ↑ Shang J, Wang G, Yang Y, Huang X, Du Z. Structure of the FP domain of Fbxo7 reveals a novel mode of protein-protein interaction. Acta Crystallogr D Biol Crystallogr. 2014 Jan;70(Pt 1):155-64. doi:, 10.1107/S1399004713025820. Epub 2013 Dec 31. PMID:24419388 doi:http://dx.doi.org/10.1107/S1399004713025820
|
